EcoDrugPlus

Chemokine (C-C Motif) Receptor 2

Ensembl ID : ENSMSIG00000021658
Gene Symbol: CCR2
1 Cross references
301 Possible Orthologues:

Chemokine (C-C Motif) Receptor 4

Ensembl ID : ENSMSIG00000007297
Gene Symbol: CCR4
1 Cross references
269 Possible Orthologues:

Chemokine (C-C Motif) Receptor 5

Ensembl ID : ENSMSIG00000021653
Gene Symbol: CCR5
1 Cross references
313 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9

Ensembl ID : ENSMSIG00000021789
Gene Symbol: CCR9
1 Cross references
277 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 1

Ensembl ID : ENSMSIG00000019993
Gene Symbol: CXCR1
1 Cross references
173 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 2

Ensembl ID : ENSMSIG00000020001
Gene Symbol: CXCR2
1 Cross references
252 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 4

Ensembl ID : ENSMSIG00000025594
Gene Symbol: CXCR4
1 Cross references
298 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSMSIG00000006255
Gene Symbol: CCKAR
1 Cross references
215 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSMSIG00000027749
Gene Symbol: CCKBR
1 Cross references
279 Possible Orthologues:

Cholinergic Receptor, Muscarinic 1, Cns

Ensembl ID : ENSMSIG00000031191
Gene Symbol: CHRM1
1 Cross references
116 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2, Cardiac

Ensembl ID : ENSMSIG00000029383
Gene Symbol: CHRM2
1 Cross references
274 Possible Orthologues:

Cholinergic Receptor, Muscarinic 3, Cardiac

Ensembl ID : ENSMSIG00000015741
Gene Symbol: CHRM3
1 Cross references
270 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).